TuHURA Biosciences (NASDAQ:HURA) Upgraded to Hold at Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently issued reports on HURA. Maxim Group reduced their price objective on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, TuHURA Biosciences has a consensus rating of “Buy” and a consensus target price of $10.33.

TuHURA Biosciences Trading Down 2.0%

HURA stock opened at $1.94 on Friday. TuHURA Biosciences has a 1-year low of $1.56 and a 1-year high of $6.90. The stock has a 50-day moving average price of $2.27 and a 200-day moving average price of $2.53. The firm has a market cap of $99.44 million, a PE ratio of -3.88 and a beta of -0.03.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01.

Institutional Trading of TuHURA Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $59,000. Jane Street Group LLC purchased a new position in TuHURA Biosciences in the 1st quarter worth approximately $69,000. Invst LLC bought a new stake in TuHURA Biosciences in the first quarter valued at approximately $61,000. Suncoast Equity Management boosted its stake in shares of TuHURA Biosciences by 4.4% during the second quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock valued at $233,000 after purchasing an additional 4,412 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of TuHURA Biosciences by 111.4% during the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares during the period. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.